Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.
InventorsGary J. Nabel, Yue Huang, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
Claims10
A method of inducing an immune response against HIV in a human, which method comprises
- (1) administering a first composition to a human, wherein the first composition comprises (a) a plasmid comprising a nucleic acid sequence encoding an HIV Env protein from Glade A, (b) a plasmid comprising a nucleic acid sequence encoding an HIV Env protein from Glade B, (c) a plasmid comprising a nucleic acid sequence encoding an HIV Env protein from Glade C, (d) a plasmid comprising a nucleic acid sequence encoding an HIV Gag protein from Glade B, (e) a plasmid comprising a nucleic acid sequence encoding an HIV Pol protein from Glade B, (f) a plasmid comprising a nucleic acid sequence encoding an HIV Nef protein from Glade B, and (g) a pharmaceutically acceptable carrier, and
- (2) administering a second composition to the human after the administration of the first composition to the human, wherein the second composition comprises (a) an adenoviral vector comprising a nucleic acid sequence encoding an HIV Env protein from Glade A, (b) an adenoviral vector comprising a nucleic acid sequence encoding an HIV Env protein from Glade B, (c) an adenoviral vector comprising a nucleic acid sequence encoding an HIV Env protein from Glade C, (d) an adenoviral vector comprising a nucleic acid sequence encoding an HIV Gag-Pol fusion protein from Glade B, and (e) a pharmaceutically acceptable carrier, whereupon an immune response against HIV is induced in the human.
Dependencies are inferred from the claim text.